InsiderTrades.com logo
Biden’s $374B Giveaway Into This Sector
From DTI   |   Ad
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Click here for the full story

ILA Insider Trading

Insider Ownership Percentage: 54.28%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Island Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Island Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Island Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 11/22/2021 11:10 AM ET

This chart shows the closing price history over time for ILA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Biden’s $374B Giveaway Into This Sector
From DTI   |   Ad
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Click here for the full story

Island Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/4/2023Albert HansenInsiderExpiry23,030A$0.07A$1,612.10
8/3/2022David FosterInsiderBuy31,303A$0.20A$6,323.21
6/21/2022David FosterInsiderBuy40,000A$0.13A$5,200.00
11/18/2021David BrookesInsiderIssued100,000A$0.25A$25,000.00
See Full Table
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
From Paradigm Press   |   Ad
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Click here to find out that this 8,788% cryptocurrency is.

SEC Filings (Institutional Ownership Changes) for Island Pharmaceuticals (ASX:ILA)

2.56% of Island Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was incorporated in 2020 and is based in Camberwell, Australia.
Read More on Island Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37

Who are the company insiders with the largest holdings of Island Pharmaceuticals?

Island Pharmaceuticals' top insider investors include:
  1. Albert Hansen (Insider)
  2. David Foster (Insider)
Learn More about top insider investors at Island Pharmaceuticals.
Biden’s $374B Giveaway Into This Sector
From DTI   |   Ad
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Click here for the full story